Benjamin Hickey - 20 Jan 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role: EVP, Chief Commercial Officer
Signature: /s/ Reena R. Desai, Attorney-inFact
Issuer symbol: N/A
Transactions as of: 20 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 24 Jan 2023, 15:00:39 UTC
Previous filing: 19 Jan 2023
Next filing: 10 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Award	$0	+36,394	+77%	$0.000000	83,617	20 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRTX	Employee Stock Option (Right to Buy)	Award	$0	+45,456		$0.000000	45,456	20 Jan 2023	Common Stock	45,456	$45.66	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.